A patient opens her fertility bloodwork, sees HIGH beside her thyroid antibodies, and wonders if she’s found the reason she hasn’t conceived, or why she miscarried. I understand that impulse. But a flagged result isn’t necessarily a diagnosis.
High thyroid antibodies but normal TSH mean your immune system is reacting against your thyroid, but the gland is still producing enough hormone. Antibodies alone aren’t a reason to start thyroid medication, and lowering the antibody number has not been shown to improve pregnancy outcomes. What matters most is your thyroid function, particularly TSH– Thyroid Stimulating Hormone, which is the signal produced from the pituitary to stimulate the thyroid gland to make thyroxine (T4), the thyroid hormone. High TSH means the thyroid gland is under-producing T4, whereas low TSH means the thyroid gland is overactive. The 2026 American Thyroid Association (ATA) guideline suggests rechecking TSH levels every three to six months while you’re trying to conceive. You have a normally functioning thyroid gland (indicated by normal range TSH levels) with positive anti-thyroid antibodies.
I’m Dr. Lucky Sekhon, a double board-certified REI specialist in New York City who has both treated patients through IVF and undergone it myself. Through my book The Lucky Egg: Understanding Your Fertility and How to Get Pregnant Now, my Instagram @lucky.sekhon, and my newsletter The Lucky Egg Drop, I cut through fertility misinformation with science-backed guidance. Thyroid antibodies are one of the most confusing results my patients bring me, so here is what they mean for miscarriage, fertility, and treatment.
High thyroid antibodies with a normal TSH mean the thyroid is under attack but still working
Your thyroid makes hormones important for metabolism, ovulation, and pregnancy. Think of it like this: TSH (thyroid-stimulating hormone) is the manager overseeing the thyroid factory. When hormone production falls behind, the brain sends a stronger TSH signal telling the factory to step up.
Thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb) indicate that the immune system recognizes thyroid tissue as a target. If TSH and free T4 remain normal, we call that euthyroid: a functioning thyroid despite positive antibodies, not hypothyroidism (ATA, 2026).
This can be an early stage of Hashimoto’s thyroiditis, but positive antibodies don’t mean someone has developed hypothyroidism, and they are common: the ATA estimates that 5–15% of women of childbearing age have positive TPO antibodies. In the trials the ATA reviewed, about 7–9% of antibody-positive women with normal thyroid function developed an underactive thyroid over a year of follow-up, which means the large majority did not.
The antibody number is not a fertility scorecard: a result of 900 doesn’t mean more thyroid damage than a result of 150, and it doesn’t dictate treatment. What I tell my patients is that elevated antibodies just put us on notice that thyroid disease can develop down the line, because your immune system appears reactive against the thyroid.
Thyroid antibodies are linked to miscarriage, but treating them has not lowered the risk
After a miscarriage, it’s understandable to look for an explanation, and for something that might prevent another loss.
There is an association between positive thyroid antibodies and pregnancy loss, even when thyroid hormone levels are normal. The 2026 ATA guideline estimates an approximately two-to-eight-percentage-point higher absolute miscarriage risk in antibody-positive versus antibody-negative women across the studies it reviewed. An older 2011 meta-analysis also found an association, although its observational studies varied considerably. The 2024 ASRM guideline characterizes the overall antibody–miscarriage evidence as conflicting.
Evidence level: suggestive, not proof of cause. Association doesn’t mean those antibodies attacked an embryo or caused an individual miscarriage, and the evidence does not support concluding that your immune system rejected your pregnancy. The ATA notes that the mechanism remains unexplained and does not appear to be mediated by reduced thyroid hormone availability.
It is the same problem as low progesterone in early pregnancy: an abnormal test can be a marker, not the cause. Loss has many possible explanations, including the reasons miscarriage can happen after a PGT-normal transfer.
Levothyroxine does not improve outcomes when antibodies are high and TSH is normal
Levothyroxine, the synthetic thyroid hormone sold as Synthroid, treats thyroid hormone deficiency. Giving it to someone whose thyroid function is normal is a different question, and it has been tested.
Evidence level: established. Three randomized controlled trials tested whether treating antibody-positive women with normal thyroid function could improve fertility or pregnancy outcomes. The results did not support treatment for antibodies alone.
The 2019 TABLET trial randomized 952 women with positive antibodies, normal thyroid function, and prior infertility or miscarriage. Live-birth rates were 37.4% with levothyroxine versus 37.9% with placebo.
The 2022 T4LIFE trial looked specifically at women with recurrent pregnancy loss and found live-birth rates of 50% with levothyroxine versus 48% with placebo. And the 2017 POSTAL trial, involving women undergoing IVF, found miscarriage rates of 10.3% with levothyroxine versus 10.6% without it.
Based on this evidence, the 2026 ATA guideline gives a strong recommendation against offering levothyroxine solely because thyroid antibodies are positive when thyroid function is normal. I follow that: I do not treat high antibodies in a patient whose TSH is where I want it, and TABLET is the reason.
This doesn’t apply to patients with actual hypothyroidism, who do need treatment. Positive antibodies alone aren’t a treatment target.
Positive thyroid antibodies lower the TSH level at which I start Synthroid
I don’t prescribe Synthroid to lower antibodies. I use antibody status for one thing: deciding how much thyroid reserve I want a patient to have before conception.
My clinical approach: With positive antibodies, I aim for a TSH below 2.5 mIU/L, and I start Synthroid if TSH is 2.5–4, even though that is inside the normal lab range. With negative antibodies, I don’t treat that range. If TSH is above 4, I recheck it with full thyroid function tests, including antibodies, and start Synthroid to bring it back under 4. For those taking levothyroxine, the ATA considers 0.5–2.5 mIU/L a reasonable preconception target.
What I do, by antibody status and TSH
| Thyroid antibodies | TSH (mIU/L) | What I do in my practice | 2026 ATA guideline |
|---|---|---|---|
| Positive | Under 2.5 | No Synthroid solely for antibodies; recheck TSH. | No levothyroxine for normal thyroid function; recheck every 3–6 months. |
| Positive | 2.5 to 4, if within the lab’s normal range | I start Synthroid, aiming for TSH under 2.5. | Does not recommend levothyroxine for antibodies alone; recheck every 3–6 months instead. |
| Positive | Above the normal range (often around 4) | I treat with Synthroid, aiming for under 2.5. | Subclinical hypothyroidism: low-dose levothyroxine can be offered without waiting for a repeat test, targeting 0.5–2.5. |
| Negative | 2.5 to 4, if normal for the lab | No Synthroid. | No levothyroxine for a normal TSH. |
| Negative | Above the normal range (often around 4) | I start Synthroid, aiming for under 4 and potentially under 2.5 before conception. | Repeat TSH and free T4 in 4–6 weeks; levothyroxine may be started if the elevation persists, targeting 0.5–2.5. |
Here is where my practice differs: the 2026 ATA guideline would watch and recheck, rather than prescribe, when antibodies are positive but TSH is 3.2 and normal for the lab. It no longer uses antibody status to guide treatment, and it found that a TSH above 2.5 did not change how women responded to levothyroxine in the trials. ASRM’s 2024 guideline also advises against treating subclinical hypothyroidism to improve pregnancy outcomes.
Evidence level: my clinical opinion, not a proven fertility benefit. My reasoning is that an autoimmune thyroid is more likely to fall behind as pregnancy increases hormone demand, so I prefer tighter control before conception to ensure an abundance of thyroid hormone for a growing fetus. But it bears mentioning that this precaution has not been shown to improve live birth rates in women whose TSH is in the normal range.
Nothing reliably lowers thyroid antibodies, and lowering them is not the goal
A positive, elevated antibody result makes selenium, gluten-free diets, and supplement stacks sound tempting. I do not recommend any intervention to lower thyroid antibody levels. The number is a marker of autoimmune activity, and there is no target antibody value that has been shown to improve your chance of having a baby.
Evidence level: suggestive for lowering the lab number, none for improving pregnancy outcomes. A 2024 meta-analysis of randomized selenium trials in Hashimoto’s thyroiditis pooled 29 study groups and 2,358 participants and found that selenium lowered TPO antibody levels, with the certainty of that evidence rated low. Changing a blood test is not the same as improving implantation, preventing miscarriage, or increasing live births, and those benefits have not been shown.
The 2026 ATA guideline finds no data that dietary interventions, selenium, steroids, or intravenous immunoglobulin improve obstetric outcomes in women with normal thyroid function and positive antibodies, and it advises against selenium supplementation for antibody-positive pregnant women.
Thyroid antibodies are worth testing after recurrent loss, with ovarian insufficiency, or when TSH is above 4
In my practice, I check thyroid antibodies in everyone being evaluated for recurrent pregnancy loss, in everyone with primary ovarian insufficiency (POI), and when TSH comes back above 4 mIU/L, in which case I repeat the TSH with full thyroid function tests. I have covered the recurrent loss workup in my Instagram videos, where thyroid testing sits alongside karyotypes, antiphospholipid antibodies, and uterine imaging as one part of a bigger picture.
Professional guidelines differ on this. The 2026 ATA guideline says TPO antibody testing may be performed in women with infertility or recurrent miscarriage. The 2024 ASRM guideline advises against antibody screening in asymptomatic women with infertility, while allowing targeted testing after recurrent loss. And although I test patients with POI, the 2024 international POI guideline advises against routine TPO antibody testing in that group. POI can result from autoimmune disease impacting the ovaries (anti-ovarian antibodies), and autoimmune diseases can be interrelated and show up together, which is why I screen for anti-thyroid and anti-adrenal antibodies in the case of POI.
TSH is often part of an initial fertility workup, especially with irregular cycles or suspected PCOS. After repeated losses, thyroid evaluation belongs alongside other investigations such as karyotype testing.
TSH needs closer monitoring through IVF and early pregnancy when antibodies are positive
A positive antibody result matters even if no medication is prescribed today, because thyroid function can change. Among women who were antibody-positive with normal thyroid function, approximately 7–9% developed subclinical or overt hypothyroidism within roughly a year in the studies reviewed by the ATA. That is why the 2026 ATA guidance suggests checking TSH and free T4 every three to six months while planning pregnancy.
My patients are usually in active treatment, so if one of them is taking Synthroid, I may check TSH every six to eight weeks, and I recheck once she is pregnant. During ovarian stimulation, estrogen levels rise, increasing the demand for thyroid hormone. In women already taking levothyroxine, the ATA reports a mean TSH rise of about 1.5 mIU/L during ovarian stimulation. That makes bloodwork timing important before IVF or embryo transfer.
Thyroid hormone requirements also rise during pregnancy. For patients already taking levothyroxine, increasing the dose at a positive pregnancy test is acceptable even before rechecking TSH; the ATA describes an increase of about 25% for women with established hypothyroidism. This is not permission to adjust your own medication. Whether to change a dose immediately, and by how much, needs to be agreed on with your doctor in advance. For someone treated for a mild TSH elevation, the same guideline notes there are no data to support a standard 25% increase, so the plan should be individualized.
Antibodies also signal a higher risk of postpartum thyroiditis, so the obstetric team should know to watch thyroid function after delivery (ATA, 2026). After an unsuccessful transfer, thyroid levels are one of the things worth rechecking; see my guide to questions worth asking before another FET.
The Bottom Line
When you see high thyroid antibodies but normal TSH, read it as a reminder to monitor your thyroid, not as the reason you haven’t conceived. Three randomized trials show that giving thyroid hormone for positive antibodies alone doesn’t improve the odds of live birth. What does change care is the TSH level: recheck it every three to six months while trying, recheck it once pregnant and then every trimester, and provide thyroid hormone supplementation if it rises to abnormal levels.
For more answers to complicated fertility questions, find me on Instagram at @lucky.sekhon, subscribe to The Lucky Egg Drop, or read my book, The Lucky Egg.





